KAMIYA BIOMEDICAL COMPANY
KAMIYA BIOMEDICAL COMPANYwas founded by Kohji Kamiya in March of 1983 in Thousand Oaks,
California, with the purpose of supplying thelife science and
medical communities with innovative laboratory research and
diagnostic tools of the highest quality. KAMIYAis an independent American company that serves worldwide markets.
The companys first products were the cutting edge protein kinase
inhibitors staurosporine and K252a for signaltransduction research.
In 1990, KAMIYAbecame the first company to introduce anti-Fas monoclonal
antibodies to the U.S. research community.
TodayKAMIYA'sproduct lines include over 1500 different preclinical testing
products, human biomarker assays,enzyme inhibitors, enzyme
substrates, monoclonal and polyclonal antibodies, and small
molecules for research in apoptosis, multidrug resistance,
oxidative / DNA damage and repair, bone biology, cancer,cardiac
health, inflammation, stress, obesity, and diabetes.
In 1993,KAMIYAintroduced a full line of clinical diagnostic and research
immunoassay products for lipid assessment,
coagulation,inflammation, diabetes, nutritional assessment, and
serum protein measurement based on immunoturbidimetrictechnology.
TheK-ASSAYs were developed for use on standard chemistry analyzers, requiring
no mixing, dissolving, or dilution ofreagent or sample, at an
KAMIYAnow has the broadest product line of liquid serum protein
immunoassay reagents of any company in the U.S., andsupplies
clinical diagnostic reagents to leading hospitals, medical centers,
clinical laboratories, clinical referencelabs, research facilities,
distributors, and diagnostic instrument companies worldwide.
Look forKAMIYA BIOMEDICAL COMPANYto continue to offer the life science and medical communities with
innovative and cutting edge laboratoryresearch and diagnostic